Conditions: Scleroderma, Systemic Sclerosis, Systemic Systemic Scleroderma Systemic Sclerosis Interstitial Lung Disease
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 23
Healthy volunteers: no

Brief summary:
The primary objective of this study is to evaluate the safety, tolerability, and efficacy of pomalidomide in the treatment of patients with systemic sclerosis with interstitial lung disease.

Detailed description:

Arms:
arm 1: None arm 2: Participants received 1 mg pomalidomide orally once a day for 52 weeks during the treatment phase and for up to 2 years during the open-label extension phase.

Interventions: intervention 1: Pomalidomide (CC-4047) intervention 2: Placebo
Intervention descriptions: intervention 1: 1 mg orally every day for 52 weeks intervention 2: Matching placebo capsules taken orally once a day

Protocol document: